CANCER

Bloodwise 34
FINANCIAL REVIEW
Beating blood cancer
Leeds
1 commitment
CHARITABLE EXPENDITURE
It’s been an exceptional year for progressing our
mission, and in spite of challenging income results
we’ve been able to invest £32.3 million in gross new
grant commitments, one of the biggest commitments
we’ve ever made (FY14: £23.2 million). This represents
a 39% increase on the previous year – the cyclical
nature of programme renewals, as well as the £6.3
million in TAP renewal have been significant drivers
for this. Over the last 5 years, new commitments have
varied between £21 million and £32 million because
of this cycle, but in total add up to more than £130
million over that period.
From the gross amount of £32.3 million we deduct
deferred commitments on programmes that are
contingent on successful completion of the early
stages of research. This is usually equivalent to two
years’ worth of a five year commitment and was £7.5
million in FY15 (FY14: £3.9 million). We also deduct
unspent funds that remain on completion of grants,
which was an unusually high figure this year at £2.1
million (FY14: £0.7 million).
The majority of our research investment is made
through UK institutions, primarily universities, and
our research investments and TAP centres are located
across the four nations of the UK.
1 commitment
Leicester
2 commitments
Birmingham
6 commitments
Oxford
5 commitments
Cardiff
1 commitment
Southampton
8 commitments
Cambridge
4 commitments
London
18 commitments
Sussex
1 commitment
See page 44 for our grant making policy.
GRANT COMMITMENTS IN
FY15 BY LOCATION
Bloodwise trading as Leukaemia & Lymphoma Research Company limited by guarantee 738089
Registered charity 216032 (England & Wales) SC037529 (Scotland)